Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 The association between CD8+ T‑cell density of the tumour

Published byMargaretMargaret Singleton Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2 The association between CD8+ T‑cell density of the tumour"— Presentation transcript:

1 Figure 2 The association between CD8+ T‑cell density of the tumour
infiltrate and overall survival among patients with primary, or metastatic solid tumours Figure 2 | The association between CD8+ T-cell density of the tumour infiltrate and overall survival among patients with primary, or metastatic solid tumours. The graph summarizes the number of articles (cited in Supplementary information S1 (table)) containing information on the influence of CD8+ T-cell density, as assessed using immunohistochemistry, on the prognosis of patients with cancer. The colour of the columns indicates a correlation between CD8+ T-cell density and a good prognosis (green), no statistically significant correlation with prognosis (white), or a correlation of CD8+ T-cell density with a poor prognosis (red). Fridman, W. H. et al. (2017) The immune contexture in cancer prognosis and treatment Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 2 The association between CD8+ T‑cell density of the tumour"

Similar presentations

Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.

Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.
Basic Immunology of the Mouse (and Human) Nicholas P. Restifo, MD October 19, 2015.

Basic Immunology of the Mouse (and Human) Nicholas P. Restifo, MD October 19, 2015.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
Figure 3 Response after appearance of a new lesion

Figure 3 Response after appearance of a new lesion
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 5 Mutational heterogeneity in oesophageal and gastric cancer

Figure 5 Mutational heterogeneity in oesophageal and gastric cancer
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 1 Key elements of cancer-related inflammation

Figure 1 Key elements of cancer-related inflammation
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Figure 1 Generations of cancer vaccine antigens

Figure 1 Generations of cancer vaccine antigens
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Monitoring clonal evolution using liquid biopsies
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Figure 2 Three-step approach to the assessment and management

Figure 2 Three-step approach to the assessment and management

Similar presentations

Ads by Google